Frequently asked questions for NHS GMC staff
These FAQs are aimed at healthcare professionals who recruit patients in the 100,000 Genomes Project. For general information about the project, please visit our taking part section.
Keep up to date
- If your question is not answered here, GMC staff can contact the Service Desk via email or call 0808 2819 535 with any queries about the 100,000 Genomes Project.
- For regular updates please subscribe to the weekly genomics email.
- Log in to NHS networks to view process maps, SOPs & contract information.
Recruitment and eligibility
Later submission of additional relatives can be advantageous as it can increase the likelihood of a diagnostic finding being identified. However, it can also delay return of results if the family is already passing through the interpretation pipeline or if the families genomes have been received back on genome build 37 (as new sequences are now received back on build 38).
If you would like to check whether to recruit an additional relative, please send a request to the Service desk with the subject line “Additional relative” along with proband participant ID of the family and the current and expected family size.
Where a further relative is to be submitted, the ‘Group type’ should be updated to reflect the new family size in the proband’s registration record before the new participant’s sample is submitted. The sample tracking system will then accept the new relative’s sample. Please note, local sample csv submission systems vary and may not be able to submit data on extra relatives. Genomics England and NHS England would be happy to discuss the steps required to address this with NHS GMCs.
Yes, as long as the proband is eligible in terms of their clinical presentation under one of the existing disease categories and they have not been given a formal molecular diagnosis, the family is eligible. The existing genetic testing result should be entered into the Genetic Tests section of the data capture tool in the usual way.
Yes, deceased probands and relatives are eligible for inclusion in the programme subject to the following conditions:
• A stored DNA sample is available which passes quality control tests
• A relative in a qualifying relationship is available to provide appropriate consent
• The consent obtained from the deceased individual at the time of sampling does not preclude use of the sample for the benefit of family members
• Surviving relatives under the care of the NHS in England will benefit in terms of healthcare or reproductive options if a diagnosis is made.
If the deceased individual had their own NHS number, please use this. If they did not have an NHS number, please use 2222222222 in the NHS number field. Please complete a data form giving details of the cause of death at the time of recruitment.
Data entry for fetuses should use the date of delivery in place of the date of birth. Forename should be entered as ‘Fetus of mother’s forename’, for example ‘Fetus of Anna’. The mother’s surname should be used for the surname. The dummy NHS number 333333333 should be used. Please complete a data form giving details of the cause of death at the time of recruitment.
There are over 5 million genetic variants in each individual’s genome and many rare diseases are caused by just one or two of these. Finding the disease-causing variant is often easier if a patient’s genome can be compared with those of their close relatives. For this reason, the majority of patients in the rare disease programme are recruited together with family members ─ a child with a rare disease, for example, with both parents.
Detailed clinical information about participants is also required to make a diagnosis for each family, as interpreting this huge amount of genome data is impossible without the ability to correlate it to the patient’s clinical condition.
Consent and ethics
Yes and yes. The Project has ethical approval for holding the consent discussion over the telephone where appropriate to the needs of the patient. You can also ask the participant to sign and return the consent form remotely, as provided for in the Protocol:
11.1.5 Giving consent by post or email In exceptional cases, some potential participants may be offered the opportunity to give consent to be part of the Project via the return of their completed consent forms to the recruiting clinician or appropriate alternative in the post/via emailed document. A telephone discussion with a suitably trained person will be offered to them as part of this, to take place at a time suited to the potential participant. This route to seeking consent will only be used where the clinical team has reason to think that seeking postal consent is an appropriate method for the individual concerned and that consent could not be sought face-to-face.
Consent is always a process, with the emphasis on the communication and the willing voluntary agreement of the participant. A record is needed of the information given to the potential participant, and that the participant has consented.
In the Project the outcome of the conversation between the recruiting clinician and the participant is recorded through the consent form. The participant signs to say they have received sufficient information and have agreed to take part in the project, and the recruiting clinician also signs. These two signatures do not have to be given at the same time or date, but need to be on the same copy of the consent form.
The preference for a sample from a BMT patient is DNA from a stored fibroblast culture, as saliva is likely to have a mixture of donor and recipient genomes, which can cause the sample to fail contamination checks and make the sequence data difficult to interpret. There is more information available in the Sample Handling Guidance. DNA which was stored before the patient had their BMT can also be sent if it passes quality control tests.
Yes, all project staff handling blood samples will follow universal precautions as in NHS laboratories, so samples from patients with infectious diseases can be included in the programme.
One of the most exciting aspects of the 100,000 Genomes Project is the fact that there are discoveries and developments just around the corner – this is a rapidly developing and cutting-edge area of medicine. In order to capitalise on these yet-unknown developments, we are examining ways to future-proof our data gathering and make sure we capture as much information relating to people’s genomes as we can. We recognise that these have the potential to add depth to the clinical interpretation of the 100,000 Genomes Project.
‘Omics’ refers to the different technologies used to characterise and quantify pools of biological molecules and to explore their roles, relationships and actions in human cells. This is done by collecting and using, with consent, high quality blood, tissue and other samples. These samples will be used to investigate whether genetic changes in patients are having a measurable effect on a patient’s blood test results, which can be used to help interpret genomic results, or to develop biomarkers to help detect and monitor disease.
Examples of ‘omics’ tests are already in clinical use. Cancers alter how a cell works, which creates new targets for new medicines and treatments. A urine test to detect molecules unique to pre-cancerous colorectal cancer polyps has been developed which is much more sensitive than existing diagnostics for early detection. The 100,000 Genomes Project is investigating whether similar tests can be done using DNA in the bloodstream to carry out an easily accessible ‘liquid biopsy’ to diagnose and monitor cancers.
These additional samples will be stored alongside patients’ genomes. It’s early days but collecting omics today is likely to provide exciting additional insights in the future into diagnosis of rare diseases and cancer that will lead to further developments in personalised medicine.
Yes, as long as each manifest is correct, omics samples do not need to be sent at the same time as the DNA sample for each participant. If a participant has been recruited using DNA only but a subsequent opportunity arises to obtain omics samples, please take the opportunity and submit these samples when they are available.
In order to make sense of the genome data, a detailed set of clinical data needs to be collected about the patient’s condition, symptoms, test results and previous negative genetic tests. For each disease in the programme, a questionnaire asking about the presence or absence of a specified set of Human Phenotype Ontology (HPO) terms is requested from GMC clinicians. HPO terms are standard ways of describing clinical features and symptoms for clinicians.
The initial HPO questionnaires were developed with the assistance of experts in the field, but many contained over 60 HPO terms, the largest being around 120 terms. This meant that they could be time-consuming for clinicians to complete. The questionnaires have now been revised to standardise the use of terms across each model and aim for a size of 20-40 terms. This has improved the quality of the questionnaires and improved the balance between depth of data and usability.
The development of these models is defining a new standardised method of clinical data collection within the NHS. This will be required for the future use of genomic tests in the diagnostic context, but will also have major benefits for future clinical care and research.
Traditionally, clinical information has been: stored on paper or in silo’d electronic health records; recorded in free text; and impossible to analyse at scale or in an anonymised way. The introduction of ontologies into medical records, and the development of standardised disease descriptions, will pave the way for effective rare disease registries in the future, making the most of every available patient cohort for future research.
Results and analysis
No, the clinical and bioinformatics teams at Genomics England will assign appropriate gene panels. The report will show which genes were analysed, and the GMC laboratory will be able to access data on other potentially relevant genes if the genes in the assigned panel(s) are insufficient for the diagnostic analysis.
The early results do not include structural or copy number variants, because these pipelines are still being developed and tested. In future these analyses will be carried out routinely. A retrospective reanalysis will be used to ensure that all participants’ genomes are analysed for structural and copy number variants; the timing of this analysis is not yet known but announcements will be made once this is underway.
Yes, if they meet the eligibility criteria for a rare disorder within the programme they can be recruited. Please select the HPO term ‘Somatic mosaicism – HP:0001442’ in the free HPO entry section of the data entry tool to indicate that you think the patient may have somatic mosaicism. The initial analysis will occur using the standard pipeline; there is currently no facility to accept a second tissue (eg fibroblast cell culture) for sequencing.